

Barbara Castella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5210175/publications.pdf>

Version: 2024-02-01

29
papers

1,039
citations

471509

17
h-index

552781

26
g-index

29
all docs

29
docs citations

29
times ranked

1883
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	2.5	16
2	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 80-89.	5.0	14
3	Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e28-e32.	2.5	13
4	Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations. <i>Journal of Immunology</i> , 2019, 202, 724-735.	0.8	13
5	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD ⁺ . <i>Oncolimmunology</i> , 2018, 7, e1458809.	4.6	59
6	V β 9V γ 2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. <i>Frontiers in Oncology</i> , 2018, 8, 508.	2.8	15
7	Increasing intratumor C/EBP- β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 286.	8.6	32
8	ABCA1, apoA-I, and BTN3A1: A Legitimate M ϕ Age Δ Trois in Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1246.	4.8	16
9	V β 9V γ 2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. <i>Frontiers in Immunology</i> , 2018, 9, 1492.	4.8	21
10	The ATP-binding cassette transporter A1 regulates phosphoantigen release and V β 9V γ 2 T cell activation by dendritic cells. <i>Nature Communications</i> , 2017, 8, 15663.	12.8	57
11	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	1.8	13
12	Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 2059-2059.	1.4	1
13	CD38 and Antibody Therapy: What Can Basic Science Add?. <i>Blood</i> , 2016, 128, SCI-36-SCI-36.	1.4	8
14	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and V β 9V γ 2 T-Cell Activation By Dendritic Cells. <i>Blood</i> , 2016, 128, 3709-3709.	1.4	0
15	Anergic bone marrow V β 9V γ 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. <i>Oncolimmunology</i> , 2015, 4, e1047580.	4.6	58
16	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1333-1343.	3.4	42
17	An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0126159.	2.5	27
18	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015, 6, 29833-29846.	1.8	33

#	ARTICLE	IF	CITATIONS
19	The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. <i>Haematologica</i> , 2014, 99, 1605-1610.	3.5	27
20	Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. <i>Molecular Cancer</i> , 2013, 12, 137.	19.2	84
21	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e60975.	2.5	49
22	Dysfunctional $V\alpha 9V\beta 2$ T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	1.4	51
23	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 3881-3881.	1.4	0
24	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012, 120, 3878-3878.	1.4	0
25	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	7.2	61
26	$V\alpha 9V\beta 2$ T cell-based immunotherapy in hematological malignancies: from bench to bedside. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2419-2432.	5.4	35
27	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between $V\alpha 9V\beta 2$ T Cells, $\hat{I}\hat{I}^2$ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. <i>Journal of Immunology</i> , 2011, 187, 1578-1590.	0.8	77
28	Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. <i>Blood</i> , 2007, 110, 921-927.	1.4	98
29	Effector $\hat{I}\hat{I}^2$ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. <i>Leukemia</i> , 2005, 19, 664-670.	7.2	119